

## **Comments on NICE Final Appraisal Determination for the Single Technology Appraisal on apremilast for moderate-to-severe plaque psoriasis**

### **British Association of Dermatologists Therapy & Guidelines and BADBIR sub-committees**

On behalf of the British Association of Dermatologists, thank you for the opportunity to comment on this Final Appraisal Determination.

We are very disappointed with the decision not to recommend apremilast for patients with moderate-to-severe plaque psoriasis.

As previously communicated during the ACD stage of this consultation, there are cohorts of patients who would benefit from the approval of apremilast, e.g. those who are not suitable for other systemic treatments or who may not meet the criteria for biological therapy or in whom biological therapy is contraindicated.

The current NICE decision yet again raises the issues of inequality for access to medication for patients as apremilast is [now available to psoriasis \(and psoriatic arthritis\) patients in Scotland](#).

The British Association of Dermatologists will not be appealing, but will be monitoring any further development with the evaluation of this drug with great interest.